CONFLICT OF INTEREST STATEMENT
Breast Cancer
ONCOLOGY, BREAST CANCER
Masaya Hattori has received honoraria from Eli Lilly and Daiichi Sankyo. Norikazu Masuda has provided leadership to Japan Breast Cancer Research Group Association (JBCRG); has received honoraria from AstraZeneca, Chugai Pharma, Eisai, Lilly Japan, and Pfizer; and has received research funding (all to institution) from AstraZeneca, Chugai Pharma, Daiichi Sankyo, Eisai, Eli‐Lilly, Kyowa‐Kirin, MSD, Novartis, Pfizer, and Sanofi. Toshimi Takano has received honoraria from Daiichi‐Sankyo, Chugai, Eisai, Eli Lilly, and Celltrion and has received research funding (all to institution) from MSD, Daiichi‐Sankyo, Chugai, Eisai, and Ono. Koichiro Tsugawa has received manuscript fees from Pfizer and Eli Lilly; has received research funding from Konica Minolta, Inc; and has received scholarship endowments/research grants from Taiho Pharmaceutical Co., ltd and Chugai Pharmaceutical Co., ltd. Kenichi Inoue has received research funding (all to institution) from Astellas, AstraZeneca, Chugai Pharma, Daiichi Sankyo, Eli‐Lilly, MSD, Novartis, Ono, Pfizer, Sanofi, Takeda, and Taiho. Koji Matsumoto has received honoraria from Kyowa‐Kirin and Chugai and has received research funding from MSD, Eli Lilly, Daiichi‐Sankyo, Chugai, Eisai, and ICON‐Japan. Takashi Ishikawa has received honoraria from Daiichi Sankyo, Kyowa Kirin, Pfizer, and Chugai. Mitsuya Itoh has no conflicts of interest. Hiroyuki Yasojima has no conflicts of interest. Yuko Tanabe has received research funding from MSD. Keiko Yamamoto is an employee of MSD K.K., Tokyo, Japan. Masato Suzuki is an employee of MSD K.K., Tokyo, Japan. Wilbur Pan is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stockholder in Merck & Co., Inc., Rahway, NJ, USA. Javier Cortes has been a consultant/advisor for Roche, Celgene, Cellestia, AstraZeneca, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Merck Sharp & Dohme, GSK, Leuko, Bioasis, Clovis Oncology, Boehringer Ingelheim, Ellipses, Hibercell, BioInvent, Gemoab, Gilead, Menarini, Zymeworks, and Reveal Genomics; has received honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp & Dohme, and Daiichi Sankyo; has received research funding (all to institution) from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman‐La Roche, Guardant health, Merck Sharp & Dohme, Pfizer, Piqur Therapeutics, Puma C, and Queen Mary University of London; has stock in MedSIR, Nektar Pharmaceuticals, and Leuko (relative); and has received travel/accommodation expenses from Roche, Novartis, Eisai, Pfizer, Daiichi Sankyo, Astrazeneca, and Gilead. In addition, Javier Cortes holds the following patents: (1) Pharmaceutical Combinations of A Pi3k Inhibitor And A Microtubule Destabilizing Agent. Javier Cortés Castán, Alejandro Piris Giménez, Violeta Serra Elizalde. WO 2014/199294 A and (2) Her2 as a predictor of response to dual HER2 blockade in the absence of cytotoxic therapy. Aleix Prat, Antonio Llombart, Javier Cortés. US 2019/ 0338368 A1. Hiroji Iwata has no conflicts of interest. The study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. All authors had access to the data from the study and had final responsibility for the decision to submit for publication.